Lululemon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

lululemon athletica inc. (NASDAQ:LULU) will release its first-quarter earnings results after the closing bell on Thursday, June 5.

Analysts expect the Vancouver, Canada-based company to report quarterly earnings at $2.59 per share, up from $2.54 per share in the year-ago period. lululemon projects to report quarterly revenue at $2.37 billion, compared to $2.21 billion a year earlier, according to data from Benzinga Pro.

On March 27, Lululemon reported fourth-quarter revenue of $3.61 billion, beating the consensus estimate of $3.57 billion. The company reported fourth-quarter earnings of $6.14 per share, beating analyst estimates of $5.85 per share, according to Benzinga Pro.

lululemon shares rose 0.1% to close at $335.19 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• Evercore ISI Group analyst Michael Binetti maintained an Outperform rating and raised the price target from $320 to $400 on June 3, 2025. This analyst has an accuracy rate of 66%.
• Citigroup analyst Paul Lejuez maintained a Neutral rating and boosted the price target from $275 to $325 on May 29, 2025. This analyst has an accuracy rate of 64%.
• Barclays analyst Adrienne Yih maintained an Equal-Weight rating and cut the price target from $309 to $276 on May 12, 2025. This analyst has an accuracy rate of 63%.
• Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and slashed the price target from $315 to $300 on April 30, 2025. This analyst has an accuracy rate of 71%.
• Goldman Sachs analyst Brooke Roach maintained a Neutral rating and cut the price target from $363 to $302 on April 22, 2025. This analyst has an accuracy rate of 65%.

Considering buying LULU stock? Here’s what analysts think:

Read This Next:

• Jim Cramer: Arrowhead Pharmaceuticals Doesn’t ‘Have The Horses’

Photo via Shutterstock